Shortened treatment for uncomplicated blood yeast infection
Part of Infections clinical trials.
This trial tests whether a shorter course of the antifungal caspofungin (7 days total) is as effective as the usual longer treatment for people with uncomplicated candidemia, a yeast infection in the blood. Participating patients must already be on caspofungin and have shown clear blood cultures for 7 days.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You are currently receiving caspofungin for a yeast infection in your blood (candidemia)
- Your blood cultures have been clear of yeast for 7 consecutive days before starting this study treatment
- Your central line (a tube inserted into a vein) has been removed or replaced within 48 hours of starting caspofungin
- You do not have complicated candidemia, such as eye infection, heart infection, or recent infection within the past 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a shorter course of antifungal medication works as well as the standard longer course for patients with a yeast infection in the blood (candidemia) that is not complicated by spread to other organs. If you have cleared the infection from your blood and are fever-free, you may be able to stop treatment sooner.
This trial compares shorter vs longer treatment for children with an uncomplicated yeast (Candida) bloodstream infection once blood cultures are clear. It may help reduce medicine exposure while keeping the infection under control.
This study compares a shorter treatment (7 days) with the standard 14-day treatment for uncomplicated candidemia, a bloodstream infection caused by Candida yeast. If you qualify, you may receive the shorter treatment, which could be just as effective with fewer side effects.
This Phase 3 trial tests fosmanogepix to treat adults with candidemia (Candida in the bloodstream) and/or invasive candidiasis (a deep Candida infection). It looks at whether the medicine is effective and safe, and whether it helps the infection improve when doctors also manage the infection source.
This study looks at patients in the intensive care unit who have a new infection with Candida (a type of fungus) despite taking strong antibiotics. It aims to better understand and diagnose these serious infections.
This study looks at how two antifungal medicines (anidulafungin and caspofungin) behave in the blood of critically ill ICU patients. It may help doctors better understand which dosing works best when patients have low blood protein levels or fluid leakage.
Hear when a new Candidemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.